The Competition Authority of Bosnia and Herzegovina prosecutes the Government of the Federation of Bosnia and Herzegovina for favouring domestic companies on the market for pharmaceuticals reimbursed under the national health insurance system

On 4 October 2012 the Competition Authority of Bosnia & Herzegovina (KV) [1] qualified the actions of the Government of Federation of Bosnia and Herzegovina (the Government) [2] that accorded preferential treatment to the domestically produced medicines under the national health insurance scheme as anticompetitive agreement under the national equivalent of Article 101 TFEU [3]. The infringement consisted in the Government’s decision to limit the number of medicines reimbursed under the national health insurance scheme and to require that domestically produced medicines have to be accorded priority when included in that number, which in some cases could lead to the exclusion of foreign medicines from the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Alexandr Svetlicinii, The Competition Authority of Bosnia and Herzegovina prosecutes the Government of the Federation of Bosnia and Herzegovina for favouring domestic companies on the market for pharmaceuticals reimbursed under the national health insurance system, 4 October 2012, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 50533

Visites 123

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues